TAAV Biomanufacturing Solutions, founded in 2019 and headquartered in San Sebastián, Spain, is a CDMO specializing in enzymatic DNA production for adeno-associated virus (AAV) gene therapies. As an alternative to plasmid DNA, the company offers a proprietary synthetic DNA molecule. This enzymatic DNA is designed to serve as an alternative to plasmid DNA in AAV production, aiming to enhance safety and efficiency, and is available in multiple grades, from research to clinical applications. In 2022, TAAV became a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio), itself a subsidiary of Bayer AG.